PMID- 36226272
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221014
IS  - 2045-1253 (Print)
IS  - 2045-1261 (Electronic)
IS  - 2045-1253 (Linking)
VI  - 12
DP  - 2022
TI  - Effect of long-acting injectable antipsychotics on hospitalizations and global 
      functioning in schizophrenia: a naturalistic mirror-image study.
PG  - 20451253221122526
LID - 10.1177/20451253221122526 [doi]
LID - 20451253221122526
AB  - BACKGROUND: Partial adherence to antipsychotics is the most common cause of 
      relapses and rehospitalization in patients with schizophrenia (SZ), leading to 
      higher health care costs and psychosocial disability. The use of long-acting 
      injectable (LAI) antipsychotics may improve therapeutic continuity and adherence 
      to treatment. OBJECTIVE: To assess the effectiveness of switching from oral 
      antipsychotics (OAs) to long-acting antipsychotics. METHODS: This 1-year 
      mirror-image study evaluated the effect of switching from OAs to LAIs on the 
      reduction of psychiatric hospitalizations and the improvement of global 
      functioning in patients with schizophrenia. Differences in outcomes between 
      second-generation (SGA) LAIs and first-generation (FGA) LAIs were also analyzed. 
      RESULTS: In all, 166 patients were included: 32.5% treated by FGA-LAIs and 67.5% 
      by SGA-LAIs. There was an overall reduction of 71% in the average number of 
      hospital admissions and an overall improvement of 29.3% in the Global Assessment 
      of Functioning (GAF) score between the previous 12 months and the 12 months 
      following the switching to LAIs. Patients who switched to SGA-LAIs had no 
      significant differences in hospitalization occurrences but a significant 
      improvement in GAF scores when compared with patients who switched to FGA-LAIs. 
      CONCLUSION: Our results suggest that using LAIs could be the most adequate 
      treatment choice for SZ patients with a high risk of relapse and low adherence 
      rate. Patients with poorer social functioning may be ideal candidates for 
      SGA-LAIs treatment. Our findings may be of particular interest from a clinical 
      and health care management perspective.
CI  - (c) The Author(s), 2022.
FAU - Montemagni, Cristiana
AU  - Montemagni C
AUID- ORCID: 0000-0003-1585-2321
AD  - Department of Neuroscience 'Rita Levi Montalcini', University of Turin, AOU Citta 
      della Salute e della Scienza, Via Cherasco N. 15, 10126 Turin, Italy.
FAU - Del Favero, Elisa
AU  - Del Favero E
AD  - Department of Neuroscience 'Rita Levi Montalcini', University of Turin, Turin, 
      Italy.
FAU - Cocuzza, Elena
AU  - Cocuzza E
AD  - Department of Mental Health, Azienda Sanitaria Locale (ASL) Citta di Torino, 
      Turin, Italy.
FAU - Vischia, Flavio
AU  - Vischia F
AD  - Department of Mental Health, Azienda Sanitaria Locale (ASL) Citta di Torino, 
      Turin, Italy.
FAU - Rocca, Paola
AU  - Rocca P
AD  - Department of Neuroscience 'Rita Levi Montalcini', University of Turin, Turin, 
      Italy.
LA  - eng
PT  - Journal Article
DEP - 20221008
PL  - England
TA  - Ther Adv Psychopharmacol
JT  - Therapeutic advances in psychopharmacology
JID - 101555693
PMC - PMC9549097
OTO - NOTNLM
OT  - functioning
OT  - long-acting antipsychotic
OT  - pharmacological treatment
OT  - psychiatric hospitalization
OT  - schizophrenia
COIS- The authors declared no potential conflicts of interest with respect to the 
      research, authorship, and/or publication of this article.
EDAT- 2022/10/14 06:00
MHDA- 2022/10/14 06:01
PMCR- 2022/10/08
CRDT- 2022/10/13 02:51
PHST- 2022/03/15 00:00 [received]
PHST- 2022/07/31 00:00 [accepted]
PHST- 2022/10/13 02:51 [entrez]
PHST- 2022/10/14 06:00 [pubmed]
PHST- 2022/10/14 06:01 [medline]
PHST- 2022/10/08 00:00 [pmc-release]
AID - 10.1177_20451253221122526 [pii]
AID - 10.1177/20451253221122526 [doi]
PST - epublish
SO  - Ther Adv Psychopharmacol. 2022 Oct 8;12:20451253221122526. doi: 
      10.1177/20451253221122526. eCollection 2022.